Invizyne Technologies, Inc. (IZTC)
| Market Cap | 106.55M |
| Revenue (ttm) | -700 |
| Net Income (ttm) | -5.12M |
| Shares Out | 8.13M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42,972 |
| Open | 13.50 |
| Previous Close | 13.00 |
| Day's Range | 13.00 - 14.18 |
| 52-Week Range | 8.50 - 14.18 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About IZTC
Invizyne Technologies, Inc. operates as a synthetic biochemical company. Its SimplePath platform produces a range of chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds, as well as consists of a series of modular cascading enzyme based biomanufacturing systems that natural processes to perform chemical conversions. The company was incorporated in 2019 and is based in Monrovia, California. [Read more]
Financial Performance
In 2023, Invizyne Technologies's revenue was $70,069, an increase of 145.01% compared to the previous year's $28,598. Losses were -$2.04 million, 46.0% more than in 2022.
Financial StatementsNews
Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq
Invizyne Technologies, Inc., a leading designer of enzyme-based biomanufacturing systems – and a...
Invizyne Technologies IPO Registration Document (S-1)
Invizyne Technologies has filed to go public with an IPO on the NASDAQ.
Biomanufacturing company Invizyne Technologies files and sets terms for a $17 million IPO
Invizyne Technologies, which is developing a biomanufacturing platform for a diverse range of chemicals, filed on Friday with the SEC to raise up to $17 million in an initial public offering.